423 related articles for article (PubMed ID: 24831734)
1. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.
Plosker GL
Drugs; 2014 May; 74(7):807-24. PubMed ID: 24831734
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
3. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
Nauck MA
Drug Des Devel Ther; 2014; 8():1335-80. PubMed ID: 25246775
[TBL] [Abstract][Full Text] [Related]
4. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
5. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Whalen K; Miller S; Onge ES
Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Stenlöf K; Cefalu WT; Kim KA; Alba M; Usiskin K; Tong C; Canovatchel W; Meininger G
Diabetes Obes Metab; 2013 Apr; 15(4):372-82. PubMed ID: 23279307
[TBL] [Abstract][Full Text] [Related]
8. Canagliflozin: first global approval.
Elkinson S; Scott LJ
Drugs; 2013 Jun; 73(9):979-88. PubMed ID: 23729000
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
Bode B; Stenlöf K; Harris S; Sullivan D; Fung A; Usiskin K; Meininger G
Diabetes Obes Metab; 2015 Mar; 17(3):294-303. PubMed ID: 25495720
[TBL] [Abstract][Full Text] [Related]
10. Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes.
Nisly SA; Kolanczyk DM; Walton AM
Am J Health Syst Pharm; 2013 Feb; 70(4):311-9. PubMed ID: 23370138
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin: A Review in Type 2 Diabetes.
Deeks ED; Scheen AJ
Drugs; 2017 Sep; 77(14):1577-1592. PubMed ID: 28836175
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Brunton S; Reid TS
Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
PLoS One; 2014; 9(8):e105638. PubMed ID: 25166023
[TBL] [Abstract][Full Text] [Related]
14. Canagliflozin: a novel treatment option for type 2 diabetes.
Dietrich E; Powell J; Taylor JR
Drug Des Devel Ther; 2013; 7():1399-408. PubMed ID: 24285921
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin: a review of its use in type 2 diabetes mellitus.
Plosker GL
Drugs; 2012 Dec; 72(17):2289-312. PubMed ID: 23170914
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
Usiskin K; Kline I; Fung A; Mayer C; Meininger G
Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
[TBL] [Abstract][Full Text] [Related]
18. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Forst T; Guthrie R; Goldenberg R; Yee J; Vijapurkar U; Meininger G; Stein P
Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
[TBL] [Abstract][Full Text] [Related]
20. [Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes].
Scheen AJ
Rev Med Liege; 2014 Dec; 69(12):692-9. PubMed ID: 25796788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]